Patents Assigned to MorphoGen Pharmaceuticals, Inc.
  • Patent number: 6214369
    Abstract: It has been discovered that mesenchymal stem cells (MSCs) in a polymeric carrier implanted into a cartilage and/or bone defect will differentiate to form cartilage and/or bone, as appropriate. Suitable polymeric carriers include porous meshes or sponges formed of synthetic or natural polymers, as well as polymer solutions. A presently preferred material is a polyglycolic acid mesh.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: April 10, 2001
    Assignee: MorphoGen Pharmaceuticals, Inc.
    Inventors: Daniel A. Grande, Paul A. Lucas
  • Patent number: 5906934
    Abstract: It has been discovered that mesenchymal stem cells (MSCs) in a polymeric carrier implanted into a cartilage and/or bone defect will differentiate to form cartilage and/or bone, as appropriate. Suitable polymeric carriers include porous meshes or sponges formed of synthetic or natural polymers, as well as polymer solutions. A presently preferred material is a polyglycolic acid mesh.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: May 25, 1999
    Assignees: Morphogen Pharmaceuticals, Inc., North Shore University Hospital Research Corporation
    Inventors: Daniel A. Grande, Paul A. Lucas
  • Patent number: 5827735
    Abstract: A scar inhibitory factor protein isolate from mammalian basement membranes is provided that inhibits lineage commitment and differentiation of stem cells in vitro and in vivo. The protein isolate is characterized by its ability to inhibit stem cell commitment to a fibroblastic-scar phenotype without killing the cells, thus allowing their differentiation into normal tissue phenotypes. SIF thus limits the amount of scar tissue formation at the site of delivery, while maximizing the potential for the stem cells to differentiate into other tissue phenotypes (muscle, cartilage, bone, fat, etc.). Therefore, it is useful in treating numerous disorders and injuries that currently result in scar tissue or fibrous adhesion formation. The protein isolate can be administered in various modalities in vivo, i.e.
    Type: Grant
    Filed: May 20, 1996
    Date of Patent: October 27, 1998
    Assignee: MorphoGen Pharmaceuticals, Inc.
    Inventors: Henry E. Young, Paul A. Lucas